Marshall Wace
EPRX

Marshall Wace’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Marshall Wace’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.14M Hold
158,133
– – ﹤0.01% 2072
2025
Q4 		$1.19M Buy
+158,133
New +$975K ﹤0.01% 1845

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Marshall Wace's EPRX Position: Q1 2026 in Review

Marshall Wace held its Eupraxia Pharmaceuticals (EPRX) position steady in Q1 2026 at 158,133 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2072.

Marshall Wace first reported a position in EPRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.19M in Q4 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Marshall Wace held 158,133 shares of Eupraxia Pharmaceuticals worth $1.14M as of Q1 2026.
  • Marshall Wace left its Eupraxia Pharmaceuticals share count unchanged in Q1 2026.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2072 holding.
  • Marshall Wace first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Marshall Wace's Eupraxia Pharmaceuticals position peaked at $1.19M in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.